75
Participants
Start Date
April 30, 2014
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
Avastin® (bevacizumab)
One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
0.9% NaCl & Refresh Liquigel
One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
New York Presbyterian Hospital, New York
Bascom Palmer Eye Institute, Miami
Massachusetts Eye and Ear Infirmary, Boston
United States Department of Defense
FED
Bascom Palmer Eye Institute
OTHER
New York Presbyterian Hospital
OTHER
Reza Dana, MD
OTHER